LDN-071 / Ladon Therap - LARVOL DELTA

LDN-071, the novel amino acid-based PAI-1 inhibitor, significantly reduces the severity of acute and chronic inflammation in colitis models (ECCO-IBD 2025) - "However, the LDN-071 reduced the expression of inflammation- and fibrosis-related genes and proteins in vitro human models. We propose that the inhibition of PAI-1 could be a potential novel therapeutic strategy in IBD."

Immunology • Inflammation • Inflammatory Bowel Disease • IL1B • IL6 • TNFA

THE NOVEL AMINO ACID-BASED PAI-1 INHIBITOR, LDN-071 SIGNIFICANTLY REDUCES THE SEVERITY OF ACUTE AND CHRONIC INFLAMMATION IN COLITIS MODELS (UEGW 2024) - "Our results showed that LDN-071, a novel amino acid-based inhibitor of PAI-1, significantly ameliorated the severity of acute and chronic colitis in mice. However, the LDN-071 reduced the expression of inflammation- and fibrosis-related genes and proteins in vitro human models. We propose that the inhibition of PAI-1 could be a potential novel therapeutic strategy in IBD."

Fibrosis • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • IL1B • IL6 • TNFA

LDN-071, a novel first-in-class amino acid-based PAI-1 inhibitor, significantly reduces the severity of experimental colitis in mice (ECCO-IBD 2024) - "It significantly reduces the severity of experimental colitis in mice. We propose that the inhibition of PAI-1 could be a potential novel therapeutic strategy in IBD."

Preclinical • Immunology • Inflammatory Bowel Disease • IL1B • IL6 • TNFA